Collection mapFoundations
Stem Cells & Perinatal Therapies · Professional series · EN
Stem cells: why the promise deserves precision
An optimistic introduction without treating a diverse scientific field as a single treatment.
On this page
The author’s perspective
I regard well-developed cell-based and perinatal therapies as a very promising area of medicine. Their appeal is not simply that they are new or “natural.” The more important possibility is that carefully characterized biological products may influence immune responses, support repair, or address needs that remain unmet by existing care. That possibility deserves serious attention—and a level of clinical judgment equal to the complexity of the science.
Optimism is not a promise of benefit from the next available vial. A scientifically interesting platform and a clinically appropriate treatment are different propositions. My approach is to ask what the proposed intervention actually is, what condition it is intended to treat, what the human evidence supports, and whether the product, setting, and follow-up meet an acceptable standard.
There is no single “stem-cell treatment”
A hematopoietic stem-cell transplant, an investigational infusion of culture-expanded stromal cells, a point-of-care bone-marrow concentrate, a placental membrane, and a placental extract can appear under the same commercial heading. They are not interchangeable interventions. Even legitimate approved cellular products have specific compositions and indications; their existence does not establish a general indication for “regeneration.” R01 R08
That distinction changes the conversation. “Do you believe in stem cells?” is not a useful clinical question. “Does this exact product have credible evidence for this patient’s actual problem?” is.
What a responsible recommendation should contain
A useful consultation should produce a reasoned conclusion, not merely a yes or no. The conclusion might be that an established center-based treatment is appropriate to discuss, that a particular research trial is a reasonable avenue, that better disease characterization is needed, or that a commercial proposal cannot be justified from the available information.
The reasoning should make uncertainty visible. It should identify the intended outcome, the quality of the comparator, the duration of follow-up, relevant safety information, and what would change the recommendation. In this series, those questions are organized around a recurring chain: condition → product → evidence → quality → clinical setting → follow-up. This is an editorial framework for reading proposals, not a validated medical score.
Two mistakes to avoid
The first mistake is to assume that an encouraging laboratory mechanism proves a useful treatment in people. The second is to assume that a disappointing product or an irresponsible clinic invalidates the entire field. Both replace discrimination with a slogan. The clinical-translation principles in the ISSCR framework emphasize responsible development and evaluation rather than treating all interventions as one category. R07
A patient may reasonably be attracted to a new approach after years of illness. Respecting that interest means explaining the options clearly, not exploiting disappointment with current treatment and not dismissing the person for asking.
How to use this series
Start with the product vocabulary before moving to a disease chapter. Then read the relevant evidence card, followed by the quality and safety chapters. A positive result from another disease, a different tissue source, or another route of administration should remain background context—not become the central justification for your own treatment.
The professional series is in English. A separate patient guide is available in English, Russian, Spanish, and Polish. PRP and extracellular-vesicle/exosome approaches are discussed only to define the boundaries of this subject; they require their own evidence reviews.
Sources
R01. FDA. Approved Cellular and Gene Therapy Products. Current product-specific register, checked September 25, 2026.
Regulator register; not a list of every procedure or tissue pathway. Access: Official product register.
R07. ISSCR. Guidelines for Stem Cell Research and Clinical Translation: Clinical Translation of Stem Cell-Based Interventions.
https://www.isscr.org/guidelines-online/clinical-translation-of-stem-cell-based-interventions
Primary professional framework for translation, manufacturing, research oversight, and informed consent. Access: Online primary guidelines.
R08. Viswanathan S, et al. Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy position statement on nomenclature. Cytotherapy. 2019;21:1019–1024. doi:10.1016/j.jcyt.2019.08.002.
https://pubmed.ncbi.nlm.nih.gov/31526643/
Primary society nomenclature statement. Access: PubMed abstract and position-statement metadata.